Exploring Dusquetide in Broader Populations PRINCETON, N.J., Aug. 15, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Dental and Craniofacial Research (NIDCR),… Read More..

SUWANEE, GA, Aug. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today announces that due to changes in reimbursement coverage in certain markets, the company is accelerating its entry… Read More..

-- First full quarter with seven products drove net product sales to $22.0 million--an increase of 196% from the second quarter 2018 -- -- Net product sales guidance between $80 and $85 million for 2019 -- -- SG&A and R&D expenses of $16.6 million for the second quarter 2019, comparable to second quarter of 2018 -- --… Read More..